Background and Purpose-Transthoracic echocardiography (TTE) is widely used in the ischemic stroke setting. In this study, we aim to investigate the yield of TTE in patients with ischemic stroke and known subtype and whether the admission troponin level improves the yield of TTE. Methods-Data were abstracted from a single-center prospective ischemic stroke database for 18 months and included all patients with ischemic stroke whose etiologic subtype could be obtained without the need of TTE. Unadjusted and adjusted regression models were built to determine whether positive cardiac troponin levels (≥0.1 ng/mL) improve the yield of TTE, adjusting for demographic and clinical characteristics. Results-We identified 578 patients who met the inclusion criteria. TTE changed clinical management in 64 patients (11.1%), but intracardiac thrombus was detected in only 4 patients (0.7%). In multivariable models, there was an association between TTE changing management and positive serum troponin level (adjusted odds ratio, 4.26; 95% CI, 2.17-8.34; P<0.001). Conclusions-In patients with ischemic stroke, TTE might lead to a change in clinical management in ≈1 of 10 patients with known stroke subtype before TTE but changed acute treatment decisions in <1 percent of patients. Serum troponin levels improved the yield of TTE in these patients.
A lthough stroke risk factor modification remains crucial for secondary stroke prevention, determining stroke mechanism is also an important step in improving stroke prevention strategies. 1, 2 After an ischemic stroke, patients undergo a diagnostic evaluation, which typically includes brain imaging, intracranial and extracranial vascular imaging, ECG, inpatient cardiac telemetry, echocardiography, and prolonged outpatient cardiac monitoring if the stroke mechanism is not determined after the initial inpatient diagnostic evaluation. Although brain and vascular imaging are often obtained in the emergency department or early after admission for ischemic stroke, obtaining echocardiography in hospitalized patients may lead to prolongation of the inpatient hospital stay. European Stroke Organization and American Heart Association guidelines recommend obtaining an echocardiogram in select patients with ischemic stroke 3, 4 Nevertheless, inpatient echocardiography is performed on a large proportion of patients with ischemic stroke. 5 In this study, we hypothesize that inpatient echocardiography will not lead to a change in the immediate clinical management in hospitalized patients with acute stroke in which the stroke etiologic subtype classification could be determined on the basis of brain, vascular imaging, and cardiac rhythm testing. In addition, we hypothesize that echocardiography
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is more likely to lead to a change in clinical management in patients with a positive admission troponin level.
Methods

Patient Population
Data were retrieved from an inpatient quality improvement prospective registry REDCap (Vanderbilt University, Nashville, TN) database (not publicly available). We included consecutive patients admitted to our facility with a diagnosis of ischemic stroke during an 18-month period. Patients underwent a standard diagnostic evaluation that included laboratory testing, brain imaging, intracranial and extracranial vascular imaging, 12-lead ECG, cardiac telemetry throughout their hospital stay, and transthoracic echocardiography (TTE). The stroke subtype was determined prospectively by the treating vascular neurology attending based on the Embolic Stroke of Unknown Source consensus criteria. 6 Because we aimed to investigate the yield of TTE in patients who received a TTE but whose stroke subtype was determined without the need of echocardiography, we only included patients with cardioembolic stroke in the setting of atrial fibrillation or atrial flutter, small vessel disease, large artery disease, or other determined mechanism. We excluded patients with cardioembolic stroke because of mechanisms detected on the inpatient TTE (low ejection fraction, severe valvular heart disease, cardiac thrombus, etc), patients with embolic stroke of unknown source where echocardiography was needed to exclude a cardioembolic source (patent foramen ovale, cardiac thrombus, etc), and patients with a known mechanical or bioprosthetic valve where echocardiography may be needed to assess the function/integrity of the valve. The study was approved by the institutional review board, and because this is a retrospective study, the need for informed consent was waived.
Primary Predictor
The primary predictor was admission cardiac troponin level defined as negative (<0.1 ng/mL) and positive (≥0.1 ng/mL).
Outcome
TTE was performed using commercially available ultrasound machines (HD15, ie33, ie33 Matrix [Phillips]; Vivid E9 [GE Healthcare]) and software (Centricity Cardio Workflow; GE Healthcare) with 2-dimensional and Doppler data recorded with a 1-to 5-MHz transducer. Images were acquired using the standard views: parasternal long and short axes; the apical 2-, 3-, and 4-chamber views; and subcostal views.
TTE was considered to have changed clinical management by (1) detecting regional wall motion abnormalities in patients without a history of coronary heart disease or myocardial infarction or ECG evidence of previous MI, (2) detecting low ejection fraction (≤40%) in patients without a known history of congestive heart failure, (3) detecting severe valvular heart disease in patients without history of valvular heart disease, or (4) detecting a cardiac thrombus. Patients with regional wall abnormalities were referred to a cardiologist for an outpatient evaluation and potentially a cardiac stress test, and those with a new diagnosis of congestive heart failure were referred to a cardiologist and started on an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker and a β-blocker. Patients with new severe valvular heart disease were referred to a cardiologist for surgical consideration. Patients in whom a cardiac thrombus was detected were started on anticoagulation therapy.
Statistical Analysis
Patients were divided into 2 groups: those in whom TTE changed management and those in whom TTE did not change management. We compared clinical characteristics, laboratory values, ECG data, and functional outcomes between the 2 groups. Prespecified multivariable logistic regression models (below) were used to estimate the association between positive troponin level and TTE findings that changed management. Analyses were performed using SPSS, version 18.0 (Chicago, IL), and P<0.05 was considered statistically significant.
Results
Baseline Characteristics of the Study Sample
We identified 647 patients who met the inclusion criteria; 578 (89.3%) had a TTE. The baseline characteristics of patients with and without TTE were similar ( 
Yield of TTE
TTE changed clinical management in 64 patients (11.1%): wall motion abnormalities in patients without known or ECG evidence of previous MI (37 patients, 6.4%), severe valvular heart disease in patients without known valvular heart disease (8 patients, 1.4%: 5 with severe aortic stenosis, 1 with severe aortic insufficiency, and 2 with severe mitral regurgitation), a low ejection fraction (≤40%) in patients without known congestive heart failure (23 patients, 4.0%), and intracardiac thrombus (4 patients, 0.7%). Of the 4 patients with intracardiac thrombus, 2 had a left atrial appendage thrombus in the setting of atrial fibrillation and 2 with large artery disease subtype had evidence of a left ventricular thrombus. Both patients with left ventricular thrombus had a positive serum troponin level. 
Univariable and Multivariable Models for Predictors of TTE Changing Management
Univariable analyses are shown in Table II in the online-only Data Supplement. A positive troponin was highly specific in predicting that TTE will change management but had low sensitivity (specificity, 0.906; sensitivity, 0.339).
In a fully adjusted analysis, there was an association between a positive troponin and a change in management (odds ratio, 4.26; 95% CI, 2.17-8.34; P<0.001; Table) . This association persisted in patients with noncardioembolic stroke only (adjusted odds ratio, 9.21; 95% CI, 1.46-57.98; P=0.018; Table) . In sensitivity analyses excluding patients with cardiac thrombus and adjusting for estimated glomerular filtration rate, the results remain unchanged.
Discussion
In this study, TTE in the setting of ischemic stroke identified covert cardiac disease and led to a change in clinical management, even in patients in whom the stroke subtype could be determined without the TTE. Patients whose TTE was more likely to lead to a change in clinical management were those with an elevated serum troponin level on admission-a biomarker of cardiac disease-with a high specificity but low sensitivity.
Although a TTE may have potentially changed management in 11.1% of patients, in the study patient cohort, it only changed acute treatment decisions in 0.7% of patients. Furthermore, the association between positive troponin and TTE changing management is not unexpected because troponin positivity may reflect underlying clinically covert cardiovascular disease. 5 Because of our small numbers and the retrospective nature of this study, larger studies or meta-analyses are needed to confirm our findings and to determine whether a negative serum troponin would help identify patients with noncardioembolic stroke in whom the TTE was expected to be low yield for findings affecting acute management. In our study, a positive troponin level had very high specificity but low sensitivity. A high-sensitivity troponin assay may improve the accuracy of predicting high-yield echocardiograms in future studies.
